Entacapone: adjunctive use in patients with advanced Parkinson's disease
Record ID 32001000040
To summarise the available evidence on entacapone (trade name Comtan(R)) for adjunctive use in patients with advanced Parkinson's disease.
Authors' recomendations: Based on current evidence, entacapone provides clinically important improvement in function for patients with Parkinson's disease suffering from symptoms of motor fluctuations. Long-term efficacy data beyond 6-month follow-up are not currently available. Entacapone was generally well tolerated in clinical trials. Most adverse events are mild and do not lead to discontinuation of treatment. The impact of entacapone on disease progression is unclear. There is no evidence to consider adjunctive therapy with entacapone at the onset of levodopa therapy. The ability of entacapone to delay the onset of motor fluctuations in PD patients not currently experiencing these fluctuations, requires further study.
Authors' methods: Overview
Project Status: Completed
URL for project: https://www.ccohta.ca/research/index.html
Year Published: 2000
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Costs and Cost Analysis
- Parkinson Disease
Organisation Name: Canadian Coordinating Office for Health Technology Assessment
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name: firstname.lastname@example.org
Contact Email: email@example.com
Copyright: Canadian Coordinating Office for Health Technology Assessment
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.